Postoperative Radiation ± Cetuximab for Head & Neck Cancer

RTOG 0920 - A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

November 22, 2017

  • Clinical Trial Information

    Trial Contact: Quintiliani, Jennifer

    Trial Phone: 321.843.2026

  • IRB No: RTOG 0920

    Protocol Abbrev: RTOG 0920

    Principal Investigator: Rafael R. Manon, MD

    Sub Investigators: Johnson, Tirrell MD; Neely, Lindsey ARNP; Rineer, Justin MD; Tseng, Jennifer MD

    Phase: Drug: Phase III

    Age Group: Adult

    Secondary Protocol No: RTOG 0920

    Treatment: Chemotherapy

    Applicable Disease Sites: Head and Neck

    Therapies Involved: Biological: cetuximab Radiation: intensity-modulated radiation therapy ID: NCT00956007

  • Objective

    This trial is studying radiation therapy to see how well it works compared with radiation therapy given together with cetuximab in treating patients who have undergone surgery for head and neck cancer.

  • Key Eligibility

    Must have histologically proven diagnosis of squamous cell carcinoma (including variants such as verrucous carcinoma, spindle cell carcinoma, carcinoma NOS, etc.) of the head/neck (oral cavity, oropharynx or larynx). Must have Clinical stage T1, N1-2 or T2-4a, N0-2, M0 including no distant metastases. Must have undergone gross total resection of the primary tumor with curative intent within the past 7 weeks.